Spermosens Operating Income from 2010 to 2026
| 9R5 Stock | 0 0.0002 16.67% |
Operating Income | First Reported 2010-12-31 | Previous Quarter -8.2 M | Current Value -8.7 M | Quarterly Volatility 3.3 M |
Check Spermosens financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spermosens' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Expense of 762 K or Selling General Administrative of 4.8 M, as well as many indicators such as . Spermosens financial statements analysis is a perfect complement when working with Spermosens Valuation or Volatility modules.
Spermosens | Operating Income |
The Operating Income trend for Spermosens AB offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Spermosens is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Spermosens' Operating Income Growth Pattern
Below is the plot of the Operating Income of Spermosens AB over the last few years. Operating Income is the amount of profit realized from Spermosens AB operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Spermosens AB is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Spermosens' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spermosens' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Spermosens Operating Income Regression Statistics
| Arithmetic Mean | (7,636,279) | |
| Coefficient Of Variation | (42.84) | |
| Mean Deviation | 2,096,864 | |
| Median | (6,151,000) | |
| Standard Deviation | 3,271,740 | |
| Sample Variance | 10.7T | |
| Range | 12.9M | |
| R-Value | (0.48) | |
| Mean Square Error | 8.7T | |
| R-Squared | 0.23 | |
| Significance | 0.05 | |
| Slope | (313,883) | |
| Total Sum of Squares | 171.3T |
Spermosens Operating Income History
About Spermosens Financial Statements
Spermosens stakeholders use historical fundamental indicators, such as Spermosens' Operating Income, to determine how well the company is positioned to perform in the future. Although Spermosens investors may analyze each financial statement separately, they are all interrelated. For example, changes in Spermosens' assets and liabilities are reflected in the revenues and expenses on Spermosens' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Spermosens AB. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Income | -8.2 M | -8.7 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Spermosens Stock
Spermosens financial ratios help investors to determine whether Spermosens Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spermosens with respect to the benefits of owning Spermosens security.